The global spirometer market size was valued at USD 1.0 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.20% from 2023 to 2030. An increase in the prevalence of chronic respiratory diseases, growing preference for home healthcare, and technological advancements are expected to drive the market. As per World Health Organization(WHO), 90% of the world's population breathes polluted air. Pollutants and irritants have various adverse effects on the lungs.
The spirometry equipment aids in the diagnosis of various respiratory diseases, such as obstructive chronic lung disease, emphysema, asthma, and other breathing disorders for screening in an occupational environment. The global increase in COPD cases is likely to increase the demand for spirometers in the coming years.
To simplify the complex procedure involved in pulmonary function testing for patients as well as medical professionals, companies are developing spirometers with improved design and features. The main objective is to develop spirometers with higher yield and improved patient comfort without complications. In addition, companies are also adopting innovative packaging procedures to prevent any type of bacterial infection. Such technological improvements make the testing procedures easier and simpler for patients.
Pandemic Impact |
Post COVID Outlook |
According to the recommendations of the New Zealand and the Irish Thoracic Society, the Thoracic Society of Australia, and the American Thoracic Society, pulmonary function tests and planned pulmonary visits were suspended/postponed during the initial months of the pandemic, except for critical cases. |
The number of patients requiring respiratory support will continue to increase for some period of time, which might result in the growing demand for spirometers. |
Incentive spirometry is usually used in patients suffering from COPD, pneumonia, acute chest syndrome, and other similar respiratory disorders. According to a research article published by the American Journal of Emergency Medicine in January 2021, researchers at the University of Illinois at Chicago have proposed the usage of incentive spirometry for the treatment of COVID-19 patients suffering from mild to moderate respiratory symptoms. |
Post pandemic, increased preference for home healthcare is expected to create new opportunities in the coming years. Hence, many manufacturers are developing spirometers for at-home use. For instance, in January 2020, the U.S. FDA approved Air Next—a wireless spirometer manufactured by NuvoAir—that is designed for at-home use by patients with cystic fibrosis, chronic obstructive pulmonary disease, and asthma, and can also transfer data to Air Next’s mobile application.
|
The use of spirometry for asthma diagnosis is not frequent in pediatric patients, especially in resource-poor countries where the burden of non-communicable diseases is higher. Strategies to increase the utilization of spirometry assessment can reduce the burden of non-communicable diseases. Thus, increased efforts to provide pediatric care and the use of modern spirometry devices that standardize test results and provide quick responses are anticipated to drive the growth of the market.
In recent years, the preference for home healthcare has increased among patients. The idea of providing treatment to patients in the comfort of their homes is a major factor propelling the growth of the market. The development of tele-spirometers is a result of the rising preference for home healthcare.
The growing elderly population is another significant driver fueling the market's growth. This population category is predisposed to a variety of chronic respiratory disorders that can be identified through spirometry. Additionally, growing consumer awareness of sophisticated diagnostic techniques is boosting the market growth.
Numerous technical improvements, such as the emergence of compact and portable spirometers that connect to smart devices, have made it possible for clinicians and hospitals to readily obtain patient data. Increased R&D to develop more efficient products is also predicted to boost the growth of the market.
The tabletop segment dominated the spirometer market and accounted for the largest revenue share of 43.6% in 2022. The market is expected to grow at a rapid pace due to its widespread application in the treatment of respiratory diseases, including asthma, COPD, and other pulmonary diseases. Portable spirometers are lightweight and compact and have become popular as these devices can store hundreds of diagnostic test results and can print the results on standard printers.
Moreover, results can be transferred to flash drives as well as to patients’ Electronic Medical Records (EMRs). Handheld portable spirometers have improved the scope of pulmonary function tests beyond the laboratory and into the primary care facilities, enabling early detection & treatment initiation for pulmonary obstructions
On the other hand, the desktop spirometers segment is expected to register the fastest growth of 10.6% compound annual growth rate (CAGR) during the forecast period as they provide integrated clinical information for enhanced clinical decisions. They can reduce the burden of paperwork. In addition, due to immediate access to patient records through the computer, clinicians can evaluate pulmonary obstruction or restriction.
Based on technology, the flow measurement segment dominated the market and accounted for a share of 66.7% in 2022. This is owing to its wide applications in pulmonary function testing. These spirometry devices are typically based on tabletop technology and have no moving parts, which makes them easier to handle.
Also, flow measurement spirometers are easy to automate as they have comparatively better frequency characteristics. In addition, they provide a graphic analysis of the flow generated during the procedure. Both inspiration and expiration are measured by flow spirometers. These devices are preferred in office and hospital settings.
The peak flow measurement segment is expected to witness the maximum growth at a 10.9% compound annual growth rate (CAGR) during the forecast period from 2022 to 2030. Peak flow measurement devices can provide warnings before an asthma attack by indicating the contraction of lung airways. Hence, medical care can be provided on time for asthma patients. Mobile applications such as Smart One enable recording of peak flow and FEV1 measurements at home, as well as electronically sending the results to the physician.
The COPD segment held the maximum market share of 40.0% in 2022. This is due to the high number of people suffering worldwide from mild to severe COPD and the easy diagnosis of COPD through spirometry. In Europe, the prevalence of COPD was estimated to be around 7.6%. Spirometry plays an extremely important role in the diagnosis and monitoring of COPD.
However, the adoption of mobile applications such as ResAppDx-capable of diagnosing COPD and aggravations of COPD due to infections-can act as an alternative and limit the segment growth.
On the other hand, the asthma segment is expected to witness the fastest growth at a 10.8% compound annual growth rate (CAGR) during the forecast period from 2023 to 2030. The economic burden caused by asthma on the NHS is around 1 billion every year. Globally, asthma incidence among children is approximately 14%, and the yearly cost of asthma treatment in the United States is over USD 18 billion.
North America dominated the market with a share of 41.6% in 2022 is mainly attributable to the increasing prevalence of respiratory diseases. Due to the increasing number of asthma and COPD cases, there has been an increase in the use of spirometers, which aid in disease control and are commonly utilized by doctors in hospitals. Additionally, the United States has been identified as an early user of technology that aid in the reduction of COPD rates. As a result of the foregoing, the market is likely to grow during the forecast period.
On the other hand, Asia Pacific is expected to witness the fastest growth at an 11.1% compound annual growth rate (CAGR) during the forecast period. Improving primary care activities for the early detection and management of chronic lung disorders such as COPD and asthma are likely to drive the Asia Pacific market during the forecast period.
The hospitals and clinics segment dominated the spirometer market with a share of 51.7% in 2022 as spirometry is extensively performed in hospitals and clinics for diagnosis and monitoring of chronic respiratory disorders. The rapidly growing aging population, the increase in reimbursements for clinical tests performed in hospitals, and the launch of advanced devices are the factors driving the growth of the segment
On the other hand, the home healthcare segment is expected to witness the highest growth at a 10.8% compound annual growth rate (CAGR) during the forecast period. Homecare for patients with respiratory diseases reduces morbidity, improves the overall quality of life, and increases their chances of survival. Spirometers used in home settings are generally battery operated and can be used daily.
The adoption of telemedicine and the launch of new products are factors likely to boost segment growth. For instance, in July 2020, a survey conducted in the U.K. revealed that CF patients monitoring their lung functions at home using NuvoAir’s smartphone application and handheld spirometer observed a 30% reduction in their scheduled & urgent in-person consultations.
The market for spirometers consists of a combination of respiratory devices manufacturers and standalone spirometer manufacturers. New technological improvements such as the adoption of artificial intelligence will create growth opportunities for new players to enter the market. For instance, NuvoAir-a Swedish respiratory health startup-developed a technology platform that enables users to conduct at-home lung function assessments.
Companies are competing to acquire the market share, especially in technologically advanced nations such as the U.K., Germany, and the U.S. The market has witnessed acquisitions and collaborations between market players to strengthen their presence. For instance, in January 2020, NuvoAir partnered with Roche Italy, wherein Roche will distribute NuvoAir’s digital respiratory technology to cystic fibrosis centers across Italy. This is expected to intensify the competition in the market over the forecast period. Some of the prominent players in the global spirometer market include:
Schiller
Smiths Medical
Vyaire Medical, Inc.
SDI Diagnostics
nSpire Health Inc.
Fukuda Sangyo Co. Ltd.
Sibelmed
Vitalograph
Geratherm Respiratory AG
Koninklijke Philips N.V.
Welch Allyn
Report Attribute |
Details |
Market size value in 2023 |
USD 1.1 billion |
Revenue forecast in 2030 |
USD 2.3 billion |
Growth Rate |
CAGR of 10.20% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2016 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, technology, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Japan; China; India; Australia, South Korea; Thailand; Brazil; Mexico; South Africa; Saudi Arabia, UAE |
Key companies profiled |
Schiller; Smiths Medical; Vyaire Medical, Inc.; SDI Diagnostics; nSpire Health Inc.; Fukuda Sangyo Co. Ltd.; Sibelmed; Vitalograph; Geratherm Respiratory AG; Koninklijke Philips N.V.; Welch Allyn |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research has segmented the global spirometer market report based on product, technology, application, end-use, and region:
Product Outlook(Revenue, USD Million, 2016 - 2030)
Devices
Hand Held
Table Top
Desktop
Software
Consumables & Accessories
Technology Outlook (Revenue, USD Million, 2016 - 2030)
Volume Measurement
Flow Measurement
Peak Flow Measurement
Application Outlook (Revenue, USD Million, 2016 - 2030)
Asthma
COPD
Cystic Fibrosis
Pulmonary Fibrosis
Others
End-use Outlook (Revenue, USD Million, 2016 - 2030)
Hospitals and Clinics
Home Healthcare
Regional Outlook (Revenue, USD Million, 2016 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Middle East & Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global spirometer market size was estimated at USD 1.0 million in 2022 and is expected to reach USD 1.1 billion in 2023.
b. The global spirometer market is expected to grow at a compound annual growth rate of 10.20% from 2023 to 2030 to reach USD 2.3 billion by 2030.
b. North America dominated the spirometer market with a share of 41.6% in 2021. This is attributable to a large patient base with respiratory disorders. In the U.S., asthma affects 25 million people and COPD affects over 12 million people.
b. Some of the key market players in the spirometer market include Smiths Medical, Schiller, SDI Diagnostics, Vyaire Medical, Inc., nSpire Health Inc., Fukuda Sangyo Co. Ltd., Sibelmed, Vitalograph, Geratherm Respiratory AG, Koninklijke Philips N.V., and Welch Allyn
b. The key factors driving the spirometer market growth include the dramatic increase in the incidence of chronic obtrusive pulmonary diseases (COPD), rising levels of air pollution, and technological improvements in monitoring solutions across the globe.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."